Genetic polymorphisms in UGT genes can significantly impact the enzyme's activity, leading to interindividual differences in drug metabolism and toxicity. Some individuals may have reduced UGT activity, which can result in slower clearance of drugs and increased risk of adverse effects. Conversely, others may have enhanced UGT activity, leading to rapid drug clearance and potentially reduced therapeutic efficacy.
